ID   M14
AC   CVCL_1395
SY   M14-MEL; UCLA-SO-M14; UCLA SO M14; UCLA-SO-14; UCLASO-M14; Melanoma 14; M-14
DR   BTO; BTO:0002805
DR   EFO; EFO_0003056
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN06129842
DR   cancercelllines; CVCL_1395
DR   Cell_Model_Passport; SIDM00003
DR   ChEMBL-Cells; CHEMBL3307591
DR   ChEMBL-Targets; CHEMBL614317
DR   Cosmic; 686479
DR   Cosmic; 687445
DR   Cosmic; 875889
DR   Cosmic; 897467
DR   Cosmic; 905975
DR   Cosmic; 974068
DR   Cosmic; 974261
DR   Cosmic; 1022278
DR   Cosmic; 1044265
DR   Cosmic; 1092611
DR   Cosmic; 1109808
DR   Cosmic; 1132591
DR   Cosmic; 1158815
DR   Cosmic; 1295340
DR   Cosmic; 1303040
DR   Cosmic; 1305365
DR   Cosmic; 1312348
DR   Cosmic; 1459642
DR   Cosmic; 1537485
DR   Cosmic; 1888913
DR   Cosmic; 1998453
DR   Cosmic; 2791112
DR   Cosmic-CLP; 905975
DR   DepMap; ACH-002159
DR   EGA; EGAS00001000978
DR   GDSC; 905975
DR   GEO; GSM2140
DR   GEO; GSM50201
DR   GEO; GSM50263
DR   GEO; GSM188222
DR   GEO; GSM188252
DR   GEO; GSM188311
DR   GEO; GSM743464
DR   GEO; GSM750799
DR   GEO; GSM799352
DR   GEO; GSM799415
DR   GEO; GSM847034
DR   GEO; GSM844583
DR   GEO; GSM1153422
DR   GEO; GSM1178326
DR   GEO; GSM1178327
DR   GEO; GSM1181292
DR   GEO; GSM1181336
DR   GEO; GSM1670072
DR   GEO; GSM2124668
DR   IARC_TP53; 18085
DR   PharmacoDB; M14_879_2019
DR   PRIDE; PXD005940
DR   PRIDE; PXD005942
DR   PRIDE; PXD005946
DR   Progenetix; CVCL_1395
DR   PubChem_Cell_line; CVCL_1395
DR   Wikidata; Q51838638
RX   DOI=10.4172/2157-7145.S2-005;
RX   PubMed=204583;
RX   PubMed=954005;
RX   PubMed=945229;
RX   PubMed=1260767;
RX   PubMed=1918136;
RX   PubMed=2041050;
RX   PubMed=2060184;
RX   PubMed=3046746;
RX   PubMed=3658923;
RX   PubMed=3674770;
RX   PubMed=6470027;
RX   PubMed=6876798;
RX   PubMed=8618233;
RX   PubMed=10700174;
RX   PubMed=11121133;
RX   PubMed=12068308;
RX   PubMed=15748285;
RX   PubMed=17088437;
RX   PubMed=18277095;
RX   PubMed=19372543;
RX   PubMed=19549886;
RX   PubMed=19727395;
RX   PubMed=19799798;
RX   PubMed=21863025;
RX   PubMed=22068913;
RX   PubMed=22347499;
RX   PubMed=22384151;
RX   PubMed=22628656;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24279929;
RX   PubMed=24670534;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=28196595;
RX   PubMed=28940260;
RX   PubMed=29492214;
RX   PubMed=30894373;
RX   PubMed=30971826;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI-60 cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 26.3 hours (NCI-DTP=M14).
CC   HLA typing: A*11:01:01,24:02:01; B*15,35; C*03:03:01,04; DPB1*13:01,19:01; DQB1*03:02,06:03; DRB1*04:05:01,13:01:01 (PubMed=15748285).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=17088437; PubMed=19799798; PubMed=29492214; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=19799798; PubMed=29492214).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (PubMed=19799798; PubMed=29492214).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=17088437; PubMed=18277095; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.64%; Native American=0%; East Asian, North=0%; East Asian, South=1.08%; South Asian=0%; European, North=67.89%; European, South=30.39% (PubMed=30894373).
CC   Derived from site: Metastatic; Right buttock, hypodermis; UBERON=UBERON_0013691+UBERON_0002072.
ST   Source(s): Cosmic-CLP; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=28940260
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D10S1248: 14
ST   D12S391: 18,19
ST   D13S317: 12
ST   D16S539: 9,13
ST   D18S51: 13,17
ST   D19S433: 14,15
ST   D1S1656: 11,12
ST   D21S11: 30
ST   D22S1045: 15
ST   D2S1338: 19,24
ST   D2S441: 11,14
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 8,10
ST   D8S1179: 13
ST   FGA: 21
ST   SE33: 15,22
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_DI53 ! MF14
OI   CVCL_DI50 ! ML14
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 39
RX   DOI=10.4172/2157-7145.S2-005;
RA   Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M.,
RA   Hart R.P., Furtado M.R.;
RT   "STR profiling of human cell lines: challenges and possible solutions
RT   to the growing problem.";
RL   J. Forensic Res. 2 Suppl. 2:5-5(2011).
RX   PubMed=204583; DOI=10.1002/ijc.2910210308;
RA   Saxton R.E., Irie R.F., Ferrone S., Pellegrino M.A., Morton D.L.;
RT   "Establishment of paired tumor cells and autologous virus-transformed
RT   cell lines to define humoral immune responses in melanoma and sarcoma
RT   patients.";
RL   Int. J. Cancer 21:299-306(1978).
RX   PubMed=954005;
RA   Zielske J.V., Golub S.H.;
RT   "Fetal calf serum-induced blastogenic and cytotoxic responses of human
RT   lymphocytes.";
RL   Cancer Res. 36:3842-3846(1976).
RX   PubMed=945229; DOI=10.1002/ijc.2910170408;
RA   Sulit H.L., Golub S.H., Irie R.F., Gupta R.K., Grooms G.A.,
RA   Morton D.L.;
RT   "Human tumor cells grown in fetal calf serum and human serum:
RT   influences on the tests for lymphocyte cytotoxicity, serum blocking
RT   and serum arming effects.";
RL   Int. J. Cancer 17:461-468(1976).
RX   PubMed=1260767;
RA   Chee D.O., Boddie A.W. Jr., Roth J.A., Holmes E.C., Morton D.L.;
RT   "Production of melanoma-associated antigen(s) by a defined malignant
RT   melanoma cell strain grown in chemically defined medium.";
RL   Cancer Res. 36:1503-1509(1976).
RX   PubMed=1918136; DOI=10.1083/jcb.115.1.191;
RA   Quax P.H.A., van Muijen G.N.P., Weening-Verhoeff E.J.D., Lund L.R.,
RA   Dano K., Ruiter D.J., Verheijen J.H.;
RT   "Metastatic behavior of human melanoma cell lines in nude mice
RT   correlates with urokinase-type plasminogen activator, its type-1
RT   inhibitor, and urokinase-mediated matrix degradation.";
RL   J. Cell Biol. 115:191-199(1991).
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D.,
RA   Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A.,
RA   Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.;
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
RX   PubMed=2060184; DOI=10.1007/BF01753729;
RA   van Muijen G.N.P., Cornelissen I.L.M.H.A., Jansen K.F.J., Figdor C.G.,
RA   Johnson J.P., Brocker E.-B., Ruiter D.J.;
RT   "Antigen expression of metastasizing and non-metastasizing human
RT   melanoma cells xenografted into nude mice.";
RL   Clin. Exp. Metastasis 9:259-272(1991).
RX   PubMed=3046746; DOI=10.1007/BF00200019;
RA   Wong J.H., Aguero B., Gupta R.K., Morton D.L.;
RT   "Recovery of a cell surface fetal antigen from circulating immune
RT   complexes of melanoma patients.";
RL   Cancer Immunol. Immunother. 27:142-146(1988).
RX   PubMed=3658923; DOI=10.1016/0143-4004(87)90053-1;
RA   Takahashi H., Adachi S., Yoshiya N., Suzuki T., Kanazawa K.,
RA   Takeuchi S.;
RT   "Expression of HLA-DR molecules in human gestational choriocarcinoma
RT   cell lines and malignant cell lines.";
RL   Placenta 8:293-298(1987).
RX   PubMed=3674770;
RA   Greco C., Zupi G.;
RT   "Biological features and in vitro chemosensitivity of a new model of
RT   human melanoma.";
RL   Anticancer Res. 7:839-844(1987).
RX   PubMed=6470027; DOI=10.1007/BF00402467;
RA   Katano M., Saxton R.E., Cochran A.J., Irie R.F.;
RT   "Establishment of an ascitic human melanoma cell line that
RT   metastasizes to lung and liver in nude mice.";
RL   J. Cancer Res. Clin. Oncol. 108:197-203(1984).
RX   PubMed=6876798; DOI=10.1002/jso.2930230404;
RA   Chee D.O., Gupta R.K., Morton D.L.;
RT   "Humoral response of melanoma patients to two different
RT   tumor-associated antigens.";
RL   J. Surg. Oncol. 23:228-235(1983).
RX   PubMed=8618233; DOI=10.1093/jnci/88.7.419;
RA   Leonetti C., D'Agnano I., Lozupone F., Valentini A., Geiser T.,
RA   Zon G., Calabretta B., Citro G., Zupi G.;
RT   "Antitumor effect of c-myc antisense phosphorothioate
RT   oligodeoxynucleotides on human melanoma cells in vitro and and in
RT   mice.";
RL   J. Natl. Cancer Inst. 88:419-429(1996).
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
RX   PubMed=11121133; DOI=10.1046/j.1523-1747.2000.00199.x;
RA   Lacal P.M., Failla C.M., Pagani E., Odorisio T., Schietroma C.,
RA   Falcinelli S., Zambruno G., D'Atri S.;
RT   "Human melanoma cells secrete and respond to placenta growth factor
RT   and vascular endothelial growth factor.";
RL   J. Invest. Dermatol. 115:1000-1007(2000).
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11.1-11.8(2005).
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K.M., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P.J.,
RA   Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
RX   PubMed=18277095; DOI=10.4161/cbt.7.5.5712;
RA   Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.;
RT   "Analysis of p53 mutation status in human cancer cell lines: a
RT   paradigm for cell line cross-contamination.";
RL   Cancer Biol. Ther. 7:699-708(2008).
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
RX   PubMed=19549886; DOI=10.1158/0008-5472.CAN-09-1528;
RA   Chambers A.F.;
RT   "MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?";
RL   Cancer Res. 69:5292-5293(2009).
RX   PubMed=19727395; DOI=10.1371/journal.pone.0006888;
RA   Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R.,
RA   Finn S.P., Loda M., Mahmood U., Ramaswamy S.;
RT   "Systems-level modeling of cancer-fibroblast interaction.";
RL   PLoS ONE 4:E6888-E6888(2009).
RX   PubMed=19799798; DOI=10.1186/1471-2407-9-352;
RA   Casula M., Muggiano A., Cossu A., Budroni M., Caraco C.,
RA   Ascierto P.A., Pagani E., Stanganelli I., Canzanella S., Sini M.C.,
RA   Palomba G., Palmieri G.;
RT   "Role of key-regulator genes in melanoma susceptibility and
RT   pathogenesis among patients from South Italy.";
RL   BMC Cancer 9:352.1-352.11(2009).
RX   PubMed=21863025; DOI=10.1038/bjc.2011.324;
RA   De Luca A., Lamura L., Strizzi L., Roma C., D'Antonio A.,
RA   Margaryan N.V., Pirozzi G., Hsu M.-Y., Botti G., Mari E., Hendrix M.J.C.,
RA   Salomon D.S., Normanno N.;
RT   "Expression and functional role of CRIPTO-1 in cutaneous melanoma.";
RL   Br. J. Cancer 105:1030-1038(2011).
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:E31628-E31628(2012).
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L.,
RA   Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C.,
RA   Wilhelm M., Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20.1-20.13(2013).
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20.1-20.11(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=28940260; DOI=10.1002/ijc.31067;
RA   Korch C.T., Hall E.M., Dirks W.G., Ewing M., Faries M., Varella-Garcia M.,
RA   Robinson S., Storts D.R., Turner J.A., Wang Y., Burnett E.C.,
RA   Healy L.E., Kniss D.A., Neve R.M., Nims R.W., Reid Y.A., Robinson W.A.,
RA   Capes-Davis A.;
RT   "Authentication of M14 melanoma cell line proves misidentification of
RT   MDA-MB-435 breast cancer cell line.";
RL   Int. J. Cancer 142:561-572(2017).
RX   PubMed=29492214; DOI=10.18632/oncotarget.23989;
RA   Sini M.C., Doneddu V., Paliogiannis P., Casula M., Colombino M.,
RA   Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G.;
RT   "Genetic alterations in main candidate genes during melanoma
RT   progression.";
RL   Oncotarget 9:8531-8541(2018).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).